Fig. 2From: Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world studyCumulative dose-related adverse events. Reported AEs with 70 mg or 140 mg erenumab per month (a), cumulative timepoints and timepoints with reported AEs depending on the respective dosage over the therapy up to 12 months (b). Reported AEs before and after increasing erenumab dosage to 140 mg per month (c)Back to article page